HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ISRG

Intuitive Surgical, Inc. (Nasdaq 100, S&P 500)

Healthcare — Medical Instruments & Supplies

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Buy 1.9 / 5 29 analysts
$361.80
+$4.97 (+1.39%)
Target: $484.60 (33.9%)
Sign in to add ISRG to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$129.62B
P/E Ratio (TTM)41.54
Forward P/E30.06
EPS (TTM)$8.71
Dividend Yield-
Profit Margin28.45%
Revenue Growth18.50%
ROE17.42%
Debt/Equity-
Recommendation Buy 1.9
Analyst Target$484.60
Analysts29
Indexes Nasdaq 100 S&P 500

Technical Indicators

RSI (14)34.7
Beta1.46
SMA 20$383.75
SMA 40$397.00
52-Week High$603.88
52-Week Low$328.57
50-Day Avg$405.58
200-Day Avg$483.56
Avg Volume$2.95M
Volume$4.08M

Performance Analysis

NEUTRAL

ISRG presents a mixed picture with both positive and negative indicators.

~ Trading at 12% of its 52-week range.
~ RSI at 34.7 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- P/E of 41.5 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 18.5% year-over-year.
+ Healthy profit margin of 28.4%.
+ Wall Street consensus is "Buy" from 29 analysts.
+ Average analyst target of $484.60 implies 33.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report